NCT00331175

Brief Summary

The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for phase_1 obesity

Timeline
Completed

Started Jul 2006

Shorter than P25 for phase_1 obesity

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2006

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 29, 2006

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2006

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
Last Updated

December 15, 2006

Status Verified

December 1, 2006

First QC Date

May 26, 2006

Last Update Submit

December 14, 2006

Conditions

Obesity

Outcome Measures

Primary Outcomes (1)

  • Food intake

Secondary Outcomes (1)

  • Plasma biomarkers, safety, toleration

Interventions

Peptide YY3-36DRUG

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI 27-35 kg/m2

You may not qualify if:

  • Women of childbearing potential

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pfizer Investigational Site

New Haven, Connecticut, United States

Location

Related Links

MeSH Terms

Conditions

Obesity

Interventions

peptide YY (3-36)

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 26, 2006

First Posted

May 29, 2006

Study Start

July 1, 2006

Study Completion

December 1, 2006

Last Updated

December 15, 2006

Record last verified: 2006-12

Locations

US(1)